AVITA Medical (RCEL) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	AVITA MEDICAL, INC.
Entity Central Index Key	0001762303
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Security Exchange Name	NASDAQ
Trading Symbol	RCEL
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		24,955,581
Entity File Number	001-39059
Entity Tax Identification Number	85-1021707
Entity Address, Address Line One	28159 Avenue Stanford
Entity Address, Address Line Two	Suite 220
Entity Address, City or Town	Valencia
Entity Address, Postal Zip Code	91355
City Area Code	(661)
Local Phone Number	367-9170

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 23,535,000	$ 55,511,000
Marketable securities	59,835,000	29,649,000
Accounts receivable, net	3,481,000	3,118,000
BARDA receivables	682,000	308,000
Prepaids and other current assets	1,146,000	1,213,000
Restricted cash	201,000	201,000
Inventory	1,803,000	2,132,000
Total current assets	90,683,000	92,132,000
Marketable securities, long-term	11,684,000	19,692,000
Plant and equipment, net	1,171,000	1,262,000
Operating lease right-of-use assets	1,375,000	1,544,000
Intangible assets, net	416,000	443,000
Other long-term assets	1,162,000	942,000
Total assets	106,491,000	116,015,000
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable and accrued liabilities	2,397,000	2,708,000
Accrued wages and fringe benefits	2,914,000	5,363,000
Other current liabilities	1,186,000	1,075,000
Total current liabilities	6,497,000	9,146,000
Contract liabilities	882,000	952,000
Operating lease liabilities, long-term	726,000	918,000
Other long-term liabilities	571,000	375,000
Total liabilities	8,676,000	11,391,000
Contingencies (Note 12)
Shareholders' Equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 24,955,581 and 24,925,743 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	3,000	3,000
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2022 and December 31, 2021
Additional paid-in capital	335,417,000	332,484,000
Accumulated other comprehensive income	7,781,000	8,060,000
Accumulated deficit	(245,386,000)	(235,923,000)
Total shareholders' equity	97,815,000	104,624,000
Total liabilities and shareholders' equity	$ 106,491,000	$ 116,015,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	24,955,581	24,925,743
Common stock shares outstanding	24,955,581	24,925,743
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 7,539	$ 8,765
Cost of sales	(1,778)	(2,146)
Gross profit	5,761	6,619
BARDA income	734	570
Operating expenses:
Sales and marketing expenses	(4,828)	(3,649)
General and administrative expenses	(7,534)	(5,422)
Research and development expenses	(3,620)	(4,109)
Total operating expenses	(15,982)	(13,180)
Operating loss	(9,487)	(5,991)
Interest expense		(3)
Other income	28	7
Loss before income taxes	(9,459)	(5,987)
Income tax expense	(4)	(10)
Net loss	$ (9,463)	$ (5,997)
Net loss per common share:
Basic	$ (0.38)	$ (0.26)
Diluted	$ (0.38)	$ (0.26)
Weighted-average common shares:
Basic	24,937,999	22,734,335
Diluted	24,937,999	22,734,335

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (9,463)	$ (5,997)
Other comprehensive income gain/(loss):
Change in foreign currency translation gain/(loss)	18	(18)
Change in net unrealized loss on marketable securities, net of tax	(297)
Comprehensive loss	$ (9,742)	$ (6,015)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2020	$ 59,597	$ 3	$ 262,086	$ 8,289	$ (210,781)
Beginning balance, shares at Dec. 31, 2020		21,625,058
Net loss	(5,997)				(5,997)
Issuance of common stock under direct placement	69,106		69,106
Issuance of common stock under direct placement, shares		3,214,250
Issuance costs associated with direct placement	(5,109)		(5,109)
Share-based compensation	1,333		1,333
Exercise of stock options	31		31
Exercise of stock options, shares		3,575
Change in foreign currency translation gain/(loss)	(18)			(18)
Ending Balance at Mar. 31, 2021	118,943	$ 3	327,447	8,271	(216,778)
Ending Balance, shares at Mar. 31, 2021		24,842,883
Beginning Balance at Dec. 31, 2021	104,624	$ 3	332,484	8,060	(235,923)
Beginning balance, shares at Dec. 31, 2021		24,925,743
Net loss	(9,463)				(9,463)
Share-based compensation	2,932		2,932
Exercise of stock options	$ 1		1
Exercise of stock options, shares	125	125
Vesting of restricted stock units, shares		29,713
Change in foreign currency translation gain/(loss)	$ 18
Other comprehensive loss	(279)			(279)
Ending Balance at Mar. 31, 2022	$ 97,815	$ 3	$ 335,417	$ 7,781	$ (245,386)
Ending Balance, shares at Mar. 31, 2022		24,955,581

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flow from operating activities:
Net loss	$ (9,463)	$ (5,997)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	163	167
Share-based compensation	2,932	1,333
Non-cash lease expense	169	156
Remeasurement and foreign currency transaction loss	37	8
Excess and obsolete inventory related charges	97	243
BARDA deferred costs	12	198
Contract cost amortization	85	50
Provision (benefit) for doubtful accounts	1	(1)
Amortization of premium of marketable securities	50
Changes in operating assets and liabilities:
Trade and other receivables	(362)	(289)
BARDA receivables	(373)	(2,810)
Prepaids and other current assets	67	(544)
Inventory	232	251
Operating lease liability	(173)	(161)
Other long-term assets	(305)	(528)
Accounts payable and accrued expenses	(294)	827
Accrued wages and fringe benefits	(2,450)	(1,833)
Other current liabilities	15	(14)
Contract liabilities	(70)	403
Other long-term liabilities	260
Net cash used in operations	(9,370)	(8,541)
Cash flows from investing activities:
Purchase of marketable securities	(25,525)
Maturity of marketable securities	3,000
Cash paid for property and equipment	(64)	(326)
Cash paid for patent filing fees	(12)	(36)
Net cash used in investing activities	(22,601)	(362)
Cash flow from financing activities:
Proceeds from direct placement of common stock		69,106
Issuance cost associated with direct placement		5,109
Proceeds from exercise of stock options	1	31
Net cash provided by financing activities	1	64,028
Effect of foreign exchange rate on cash and restricted cash	(6)	(11)
Net decrease in cash and cash equivalents and restricted cash	(31,976)	55,114
Cash and cash equivalents and restricted cash beginning of the period	55,712	59,966
Cash and cash equivalents and restricted cash end of the period	23,736	115,080
Supplemental Disclosure of Cash Flow Information
Cash paid for interest		3
Plant and equipment purchases not yet paid	$ 8	$ 27

The Company

The Company	3 Months Ended
	Mar. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	1. The Company Nature of the Business The AVITA group of companies (comprising AVITA Medical, Inc. (“AVITA” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited, previously known as AVITA Medical Limited, (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a commercial-stage regenerative medicine company focused on the treatment of burns, trauma and other acute injuries, together with skin defects like vitiligo. The Company’s lead product is the RECELL® System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute thermal burns in patients eighteen years and older. Following receipt of our original In February 2022, the FDA approved a PMA supplement for the RECELL® Autologous Cell Harvesting Device with enhanced ease-of-use, aimed at providing clinicians a more efficient user experience and simplified workflow. In February 2019 we entered into a collaboration with COSMOTEC, an M3 Group company, to market and distribute the RECELL System in Japan. We worked with COSMOTEC to advance our application for approval of the RECELL System in Japan pursuant to Japan’s Pharmaceuticals and Medical Devices Act (“PMDA”). In February 2022, COSMOTEC’s application for regulatory approval was approved by the PMDA initially with labelling for burns only. COSMOTEC plans to commercially launch RECELL in Japan following Japan’s Ministry of Health, Labour, and Welfare approval of reimbursement pricing. Once soft tissue and vitiligo data are available from the Company’s related U.S. clinical trials, COSMOTEC plans to submit a further application for soft tissue and vitiligo indications. In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“ COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP SEC Transition Report There have been no changes to the Company’s significant accounting policies as described in the T ransition R eport on Form 10-K T that have had a material impact on the Company’s consolidated financial statements . See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the Transition Report. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated on consolidation. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, and the stand-alone selling price for the BARDA contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts. Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive gain (loss) in shareholders’ equity. Gains and losses resulting from foreign currency transactions are included in general and administrative expenses and were a loss of $22,000 and gain of $8,000 for the three months ended March 31, 2022 and 2021, respectively. The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements and foreign currency transactions are included in general and administrative expenses. During the three months ended March 31, 2022 and 2021, the Company recorded losses of $15,000 and $16,000, respectively. Comprehensive Income (Loss) The components of comprehensive income (loss) consist of net income (loss), foreign currency translation adjustments from its subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available for sale. The Company did not have reclassifications from other comprehensive income (loss) to net loss during the quarter ended March 31, 2022. Revenue Recognition The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ASC”) Topic 606, Revenue Recognition, the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as performance obligation(s) are satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company’s revenue consists primarily of the sale of the RECELL System to hospitals or other treatment centers and to BARDA (collectively, “customers”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606. Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the consolidated statement of operations and are accounted for under IAS 20. For further details refer to BARDA Income and Receivables below. Revenues for commercial customers (hospitals and treatment centers) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. For the Company’s contracts that have an original duration of one year or less, the Company elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred. For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services. Through this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, overtime as services are consumed. The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606, was determined to be $9.2 million. The transaction price was allocated on a stand-alone selling price basis as follows: $7.6 million to the procurement of the RECELL product, which is classified as revenues when recognized in the consolidated statement of operations and $1.6 million to the emergency deployment services which is classified as revenues when recognized in the consolidated statement of operations. The $1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole. The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. Securities and Exchange Commission (SEC) Interpretation, Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS). Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 days, and do not include a financing component. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized. Income Taxes Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. The Company reviews its uncertain tax positions regularly. An uncertain tax position represents the Company’s expected treatment of a tax position taken in a filed return or planned to be taken in a future tax return or claim that has not been reflected in measuring income tax expense for financial reporting purposes. The Company recognizes the tax benefit from an uncertain tax position when it is more-likely-than-not that the position will be sustained upon examination on the basis of the technical merits or the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired. Cash and Cash Equivalents Consists of cash held at deposit institutions and cash equivalents. Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $6.9 million and $4.4 million of which $760,000 and $203,000 is denominated in foreign currencies in foreign institutions as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022 and December 31, 2021, the Company held cash equivalents in the amount of $16.6 million and $51.1 million, respectively. Restricted Cash Pursuant to a contractual agreement to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $201,000 as of March 31, 2022 and December 31, 2021, respectively. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of March 31, 2022 and December 31, 2021, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of March 31, 2022 no single commercial customer accounted for more than 10% of total revenues or net accounts receivable. BARDA revenue for emergency deployment accounted for approximately 1% and 47% of total revenues for the three months ended March 31, 2022 and 2021, respectively. BARDA receivables for emergency preparedness services accounted for 1% and 3% of total BARDA receivables as of March 31, 2022 and December 31, 2021, respectively. See table below for breakdown of BARDA receivables (in thousands). As of March 31, 2022 As of December 31, 2021 BARDA procurement and emergency preparedness services $ 8 $ 9 BARDA expense reimbursements 674 299 Total BARDA receivables $ 682 $ 308 Marketable Securities We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date. Classification is determined at the time of purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations. We account for our marketable securities as available-for-sale securities. All marketable securities, which consist of corporate debt securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in the U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders equity until realized. Realized gains and losses on marketable securities are included in other income in the accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in other income. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months. If necessary, the Company will recognize an allowance for credit losses on available-for-sale debt securities on an individual basis, and will no longer consider other than-temporary impairment or immediately reduce the cost basis of the investment provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates. To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available for sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through other income. BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee. The Company has concluded that grants under the BARDA arrangement are not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition Accounting for Government Grants and Disclosure of Government Assistance, Leases The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company’s operating leases have remaining lease terms of one year to two years, some of which include options to renew the lease. At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. Right of use (“ ROU IBR The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in general and administrative expenses in the accompanying consolidated statements of operations. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease assets or liabilities. Variable lease costs are expensed when incurred. Share-based compensation The Company records compensation expense for stock options based on the fair market value of the awards on the date of grant. The fair value of share-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is measured based on the number of shares ultimately expected to vest, estimated at each reporting date based on management’s expectations regarding the relevant performance criteria, if any. The Black-Scholes option pricing model and Monte Carlo Simulation were used to estimate the fair value of the time-based and performance-based options, respectively. Under ASU 2016-09, Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting The following assumptions were used in the valuation of stock options. • Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months. • Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future • Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, the first plan was established in 2016 and was primarily used for Executives awards. Further, the Company does not have sufficient history of exercises in the U.S. market given the recent redomiciliation to the United States during 2020. The expected term of options with a performance condition was set to the contractual term of 10 years. • Risk-free interest rate – t he risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award. Segment Reporting Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as one segment. Deferred Compensation Plan and Investments in Corporate-Owned Life Insurance The Company’s Deferred Compensation Plan (the " DCP Compensation – Retirement Benefits two-years accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to compensation liability with corresponding credit to cash. The Company funds the DCP through a Corporate-Owned Life Insurance ( COLI ). Per the ASC 325-30-25-1A , Investments – Other , COLI is recorded as an asset in ther ong- erm assets as it does not meet the definition of a plan asset under ASC 715. COLI

Accounting Standards Update

Accounting Standards Update	3 Months Ended
	Mar. 31, 2022
Accounting Changes And Error Corrections [Abstract]
Accounting Standards Update	3. Accounting Standards Update Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, “ Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes The Company adopted this standard as of January 1, 2022. The adoption did not have a material impact on the Consolidated Financial Statements. Recent Accounting Pronouncements Not Yet Adopted All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2022
Available For Sale Securities [Abstract]
Marketable Securities	4. Marketable Securities The following table summarizes the amortized cost and estimates fair values of debt securities available for sale: March 31, 2022 Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Carrying Value (in thousands) Cash Equivalents: Money market funds $ 16,617 $ - $ - $ 16,617 Current marketable securities: U.S Treasury securities $ 27,246 $ 1 $ (114 ) $ 27,133 Commercial paper 21,331 - - 21,331 Corporate debt securities 9,517 1 (43 ) 9,475 U.S Government Agency Obligations 1,906 - (10 ) 1,896 Total current marketable securities $ 60,000 $ 2 $ (167 ) $ 59,835 Long-term marketable securities: U.S Treasury securities $ 10,990 $ - $ (234 ) $ 10,756 Corporate debt securities 931 - (3 ) 928 Total Long-term marketable securities $ 11,921 $ - $ (237 ) $ 11,684 As of December 31, 2021 Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Carrying Value (in thousands) Cash Equivalents: Money market funds $ 51,112 $ - $ - $ 51,112 Current marketable securities: Commercial paper $ 19,586 $ - $ - $ 19,586 Corporate debt securities 7,068 - (7 ) 7,061 Asset-backed securities 3,002 - - 3,002 Total current marketable securities $ 29,656 $ - $ (7 ) $ 29,649 Long-term marketable securities: U.S Treasury securities $ 18,043 $ - $ (89 ) $ 17,954 Corporate debt securities 1,746 - (8 ) 1,738 Total Long-term marketable securities $ 19,789 $ - $ (97 ) $ 19,692 The maturities of debt securities available for sale are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of March 31, 2022 As of December 31, 2021 Amortized Cost Carrying Value Amortized Cost Carrying Value Due in one year or less 60,000 59,835 $ 29,656 $ 29,649 Due after one year through three years 11,921 11,684 $ 19,789 $ 19,692 Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $2,000 and an unrealized loss of $404,000 as of March 31, 2022 which resulted in a net unrealized loss of $402,000. During the three months ended March 31, 2022, the Company did not recognize credit losses. Gross unrealized gains and losses on the Company’s marketable securities were an unrealized gain of $0 and an unrealized loss of $104,000 as of December 31, 2021 which resulted in a net unrealized loss of $104,000. During the transition period ended December 31, 2021, the Company did not recognize credit losses. The Company has accrued interest income of $123,000 and $72,000 as of March 31, 2022 and December 31, 2021, respectively, recorded in Prepaids and Other Current Assets.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs are unobservable inputs for the asset or liability The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash Equivalents Money market funds $ 16,617 $ - $ - $ 16,617 Total cash equivalents 16,617 - - 16,617 Short-term marketable securities U.S Treasury securities - 27,133 - 27,133 Commercial paper - 21,331 - 21,331 Corporate debt securities - 9,475 - 9,475 U.S Government Agency Obligations - 1,896 - 1,896 Total short-term marketable securities - 59,835 - 59,835 Long-term investments U.S Treasury securities - 10,756 - 10,756 Corporate debt securities - 928 - 928 Total long-term marketable securities - 11,684 - 11,684 Total marketable securities and cash equivalents $ 16,617 $ 71,519 $ - $ 88,136 As of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash Equivalents Money market funds $ 51,112 $ - $ - $ 51,112 Total cash equivalents 51,112 - - 51,112 Short-term marketable securities Commercial paper - 19,586 - 19,586 Asset-backed securities - 3,002 - 3,002 Corporate debt securities - 7,061 - 7,061 Total short-term marketable securities - 29,649 - 29,649 Long-term investments U.S Treasury securities - 17,954 - 17,954 Corporate debt securities - 1,738 - 1,738 Total long-term marketable securities - 19,692 - 19,692 Total marketable securities and cash equivalents $ 51,112 $ 49,341 $ - $ 100,453 The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of commercial paper, U.S Government agency obligations, corporate debt securities and U.S Treasury securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of March 31, 2022 and December 31, 2021, the Company had no investments that were measured using unobservable (Level 3) inputs. There were no transfers between fair value measurement levels during the quarter ended March 31, 2022 or the transition period ended December 31, 2021.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	6. Leases During August 2021, the Company remeasured the lease liability for an office lease due to a change in the lease term. As a result of the remeasurement of the lease liability, there was an increase of approximately $392,000 to the operating lease ROU assets and operating lease liabilities. There was no impact on earnings as a result of the modification. The following table sets forth the Company’s operating lease expenses which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Three months ended March 31, 2022 2021 Operating lease cost $ 194 $ 186 Variable lease cost 13 12 Total lease cost $ 207 $ 198 Supplemental cash flow information related to operating leases for the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three months ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 198 $ 191 Supplemental balance sheet information, as of March 31, 2022 and December 31, 2021 related to operating leases was as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Reported as: Operating lease right-of-use assets $ 1,375 $ 1,544 Total right-of-use assets $ 1,375 $ 1,544 Other current liabilities: Operating lease liabilities, short-term $ 738 $ 720 Operating lease liabilities, long term 726 918 Total operating lease liabilities $ 1,464 $ 1,638 Operating lease weighted average remaining lease term (years) 2.07 2.30 Operating lease weighted average discount rate 6.54 % 6.51 % As of March 31, 2022, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases 2022 $ 604 2023 649 2024 313 2025 - Total lease payments 1,566 Less imputed interest (102 ) Total operating lease liabilities $ 1,464 As of March 31, 2022, there were no leases entered into that had not yet commenced.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	7. Inventory The composition of inventory is as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Raw materials $ 1,256 $ 1,222 Work in process 439 176 Finished goods 108 734 Total inventory $ 1,803 $ 2,132 The Company has reduced the carrying value of its inventories to reflect the lower of cost or net realizable value. Charges for estimated excess and obsolescence are recorded in cost of sales in the consolidated statement of operations and were $97,000 and $243,000, for each of the three months ended March 31, 2022 and March 31, 2021, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets The composition of intangible assets, net is as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Weighted Average Life Gross Amount Accumulated Amortization Net Carry Amount Gross Amount Accumulated Amortization Net Carry Amount Patent 1 2 $ 211 $ (210 ) $ 1 $ 209 $ (182 ) $ 27 Patent 2 11 128 (19 ) 109 123 (18 ) 105 Patent 3 14 192 (28 ) 164 192 (25 ) 167 Patent 5 20 46 (4 ) 42 46 (3 ) 43 Patent 6 20 39 (3 ) 36 39 (2 ) 37 Patent 7 13 2 - 2 2 - 2 Patent 8 20 3 - 3 3 - 3 Patent 10 19 3 - 3 3 - 3 Patent 11 19 6 - 6 6 - 6 Trademarks Indefinite 50 - 50 50 - 50 Total intangible assets $ 680 $ (264 ) $ 416 $ 673 $ (230 ) $ 443 During the three months ended March 31, 2022 and 2021, the Company did not identify any events or changes in circumstances that indicated that the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the three months ended March 31, 2022 and 2021. Amortization expense of intangibles included in the consolidated statements of operations was $34,000 and $30,000 for the three months ended March 31, 2022 and 2021, respectively. The Company expects the future amortization of amortizable intangible assets held at March 31, 2022 to be (in thousands) Estimated Amortization Expense 2023 30 2024 30 2025 30 2026 30 2027 30 Thereafter 216 Total $ 366

Plant and Equipment

Plant and Equipment	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Plant and Equipment	9. Plant and Equipment The composition of property, plant and equipment, net is as follows (in thousands): Useful Lives As of March 31, 2022 As of December 31, 2021 Computer equipment 3 years $ 750 $ 740 Computer software 3 years 811 811 Construction in progress - 29 Furniture and fixtures 7 years 440 440 Laboratory equipment 5 years 623 566 Leasehold improvements Lesser of life or lease term 242 242 RECELL Moulds 5 years 129 129 Less: accumulated amortization and depreciation (1,824 ) (1,695 ) Total plant and equipment, net $ 1,171 $ 1,262 Depreciation expense related to plant and equipment for the three months ended March 31, 2022 and 2021 was $129,000 and $137,000, respectively.

Prepaids and Other Current Asse

Prepaids and Other Current Assets and Other Long-Term Assets	3 Months Ended
	Mar. 31, 2022
Prepaids And Other Current Assets And Other Long Term Assets [Abstract]
Prepaids and Other Current Assets and Other Long-Term Assets	10. Prepaids and Other Current Assets and Other long-term assets Prepaids and other current assets consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Prepaid expenses $ 994 $ 1,124 Lease deposits 2 2 Accrued investment income 123 72 Other receivables 27 15 Total prepaids and other current assets $ 1,146 $ 1,213 Prepaid expenses primarily consist of prepaid benefits and insurance. Other long-term assets consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2021 BARDA contract costs $ 441 $ 504 Corporate-owned life insurance policies 586 304 Long-term lease deposits 124 124 Long-term prepaids 11 10 Total other long-term assets $ 1,162 $ 942

Reporting Segment and Geographi

Reporting Segment and Geographic Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	11. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets are primarily located in the United States as of March 31, 2022 and 2021 with an insignificant amount located in Australia and the United Kingdom. Revenue by region for the three months ended March 31, 2022 and 2021 were as follows (in thousands): Three months ended March 31, 2022 2021 Revenue: United States $ 7,398 $ 8,725 Foreign: Australia 87 25 United Kingdom 54 15 Total $ 7,539 $ 8,765 Revenue and Cost of sales by Customer type for the three months ended March 31, 2022 and 2021 were as follows (in thousands): Three months ended March 31, 2022 2021 Revenue: Commercial sales $ 7,446 $ 4,622 BARDA: Product sales - 4,085 Services for emergency preparedness 93 58 Total $ 7,539 $ 8,765 Three months ended March 31, 2022 2021 Cost of sales Commercial cost $ 1,705 $ 966 BARDA: Product cost (12 ) 1,130 Emergency preparedness service cost 85 50 Total $ 1,778 $ 2,146

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of March 31, 2022 and December 31, 2021, the Company did not have any outstanding or threatened litigation that would have a material impact to the financial statements.

Common and Preferred Stock

Common and Preferred Stock	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Common and Preferred Stock	13. Common and Preferred Stock The Company’s CHESS Depositary Interests ("CDIs") are quoted on the ASX under the ticker code, “AVH”. The Company’s shares of common stock are quoted on NASDAQ under the ticker code, “RCEL”. One share of common stock on NASDAQ is equivalent to five CDIs on the ASX. As a result of the ‘implicit consolidation’ that occurred under the AVITA group's redomiciliation from Australia to the United States of America, the number of shares of common stock on issue in the Company (as set out in the consolidated financial statements) is less than the number of ordinary shares in AVITA Medical (the prior parent company of the AVITA group) that was previously set out in the consolidated financial statements of AVITA Medical. All common share amounts included in the consolidated financial statements have been retroactively reduced by a factor of one hundred and all per share amounts have been increased by a factor or one hundred, with the exception of the Company’s common stock par value. The Company is authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of March 31, 2022, and December 31, 2021, 24,955,581

Revenues

Revenues	3 Months Ended
	Mar. 31, 2022
Revenue Performance Obligation [Abstract]
Revenues	14. Revenues Revenues The Company’s revenue consists of sale of the RECELL System to hospitals or other treatment centers and to BARDA (collectively “ customers Performance Obligations For commercial contracts, we identified the hospital or treatment center as the customer in Step 1 of the 5-step model of ASC 606 and have determined a contract exists with those customers. As these contracts typically have a single performance obligation (i.e. product delivery), no allocation of the transaction price is required in Step 4 of the model. Control of the product is transferred to the customer at a point in time, at the point in time at which the goods are either shipped or delivered to our customers’ facilities, depending on the terms of the contract. The transaction price is stated within the contract and is therefore fixed consideration. The transaction price does not include the sales tax that are imposed by governmental authorities. For the contract with BARDA, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services. Remaining Performance Obligations Revenues from remaining performance obligations are calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $882,000 and $952,000 as of March 31, 2022 and December 31, 2021, respectively. Approximately $447,000 for March 31, 2022 and $517,000 for December 31, 2021 of the total balance relates to our July 2020 contract with BARDA for the purchase, delivery and storage of RECELL Systems for emergency response preparedness for a period of three years. The Company expects to recognize this amount as services are provided to BARDA. For the remaining balance of $435,000 as of March 31, 2022 and December 31, 2021, the Company expects to recognize revenue on a straight-line basis over the term of the contract upon generation of sales for with Cosmotec. For the contract with BARDA, we recognized $93,000 and $58,000 of service revenue related to the emergency readiness performance obligation during the three months ended March 31, 2022 and 2021. We are contracted to manage this inventory of product until the federal government requests shipment or at contract termination on December 31, 2023. Variable Consideration The Company evaluates its contracts with customers for forms of variable consideration, which may require an adjustment to the transaction price based on their estimated impact. For commercial customers, revenue from the sale of goods is recognized net of volume discounts. The Company uses the expected value method when estimating variable consideration. Revenue is only recognized to the extent that it is probable that a significant reversal will not occur. Variable consideration under the BARDA contract is not material to the consolidated financial statements. Contract Assets and Contract Liabilities Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of the period ended March 31, 2022 and December 31, 2021, the Company does not have any contract assets. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $882,000 and $952,000 of contract liabilities as of March 31, 2022 and December 31, 2021, respectively. The balance relate to the unsatisfied performance obligation for emergency preparedness under the BARDA contract and Cosmotec. Performance obligation will be satisfied, and revenue will be recognized over time over the term of the contract. For the three months ended March 31, 2022 and 2021, the Company recognized $93,000 and $58,000 of revenue from amounts included in the beginning balance of contract liabilities. Cost to Obtain and Fulfill a Contract Commercial contract fulfillment costs include commissions and shipping expenses. The Company has opted to immediately expense the incremental cost of obtaining a contract when the underlying related asset would have been amortized over one year or less. The Company generally does not incur costs to obtain new contracts. BARDA Contract Costs Cost to fulfill the BARDA emergency preparedness performance obligation, which primarily consist of billed costs to BARDA incurred in connection with the emergency deployment services, are incremental and expected to be recovered. Costs are capitalized and amortized on a straight-line basis over the term of the contract. As of March 31, 2022 and December 31, 2021, the Company had Disaggregated Revenue The Company disaggregates revenue from contracts with customers into geographical regions and by customer type. As noted in the segment footnote, the Company’s business consists of one reporting segment. A reconciliation of disaggregated revenue by geographical region and customer type is provided in Segment Note 11.

Share-Based Payment Plans

Share-Based Payment Plans	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Payment Plans	15. Share-Based Payment Plans Overview of Employee Share-Based Compensation Plans Our former parent company, AVITA Medical, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the “ 2016 Plans 2020 Plan The 2020 Plan provides for the grant of the following Grants: (a) Incentive Stock Options, (b) Nonstatutory Stock Options, (c) Stock Appreciation Rights, (d) Restricted Stock Grants, (e) Restricted Stock Unit Grants, (f) Performance Grants, and (g) Other Grants. The 2020 Plan will be administered by the Compensation Committee or by the Board acting as the Compensation Committee. Subject to the general purposes, terms and conditions of the 2020 Plan, applicable law and any charter adopted by the Board governing the actions of the Compensation Committee, the Compensation Committee will have full power to implement and carry out the 2020 Plan. Without limitation, the Compensation Committee will have the authority to, interpret the plan, approve persons to receive grants, determine the terms and number of shares of the grants, determine vesting and exercisability of grants, and make all other determinations necessary or advisable in connection with the administration of this Plan. The contractual term of awards granted under the 2020 Plan is ten years from the date of its grant. Unless otherwise specified, the vesting period of awards under the 2020 Plan was: (i) vest over a four year period in four equal installments, 25% at the end of each year from the date of grant, and /or (ii) subject to other performance criteria and hurdles, as determined by the Compensation Committee. Share-Based Payment Expenses Share-based payment transactions are recognized as compensation expense based on the fair value of the instrument on the date of grant. The Company uses the graded-vesting method to recognize compensation expense The Company has included share-based compensation expense as part of operating expenses in the accompanying consolidated statements of operations as follows (in thousands): Three-months ended March 31, 2022 2021 Sales and marketing expenses $ 329 $ 238 General and administrative expenses 2,327 930 Research and development expenses 276 165 Total $ 2,932 $ 1,333 A summary of share option activity as of March 31, 2022 and changes during the period ended is presented below: Service Only Share Options Performance Based Share Options Market Awards Total Share Options Outstanding shares at December 31, 2021 1,129,126 599,994 27,600 1,756,720 Granted 21,900 - - 21,900 Exercised (125 ) - - (125 ) Expired (2,275 ) - - (2,275 ) Forfeited (5,050 ) - - (5,050 ) Outstanding shares at March 31, 2022 1,143,576 599,994 27,600 1,771,170 Exercisable at March 31, 2022 592,085 319,219 - 911,304 Restricted Stock Units Restricted stock units (“ RSUs A summary of the status of the Company’s unvested RSUs as of March 31, 2022, and changes that occurred during the year is presented below: Service Condition RSU Performance Condition RSU Market Condition Total RSU's Unvested RSUs outstanding at December 31, 2021 114,757 135,093 47,640 297,490 Vested - (29,713 ) - (29,713 ) Unvested RSUs outstanding at March 31, 2022 114,757 105,380 47,640 267,777 2019 On November 2019, the equivalent of 395,542 RSUs were issued to the CEO with the following vesting terms: a) Tenure – the equivalent of 142,521 RSUs with a vesting period of three-years b) Milestone performance – 253,021 of the RSUs will vest upon satisfaction of various performance conditions. As of March 31, 2022 all milestones have been achieved and have been released. 2021 AGM Awards On December 22, 2021, as part of the Company's 2021 AGM, the Company's stockholders approved the grant of stock option awards and RSUs to the CEO and the Board of Directors. These awards are referred to as the 2021 AGM awards. Awards to the CEO under the 2021 AGM Awards On December 22, 2021, the CEO was issued an aggregate 150,480 options and RSUs comprising: • 37,600 • 37,640 o 9,410 options) - Achieve Centers for Medicare and Medicaid Services reimbursement for out-patient transitional pass-through payment code (TPT) by June 30, 2022 – 9,410 awards Performance condition was met during the quarter ended March 31, 2022 resulting in the 5,960 shares of common stock being issued in respect of the RSUs and the 3,450 options vesting (although they have not been exercised by the CEO as at the date of this Form 10-Q). o 9,410 o 9,410 o 9,410 • 75,240 o 37,620 (23,820 RSUs and 13,800 options) - Achieve a doubling based on a 10-day volume-weighted average price (“VWAP”) of the Company’s share price as of the date of the 2021 Annual Meeting (being December 14, 2021) by June 30, 2023. The target share price is $25.74. o 37,620 In order for any options or RSUs issued to the CEO to vest, both the service condition and the relevant performance or market condition (as set out in the relevant agreement between the Company and the CEO) must be satisfied. The market awards will partially vest upon satisfaction of the market condition, and the other portions will vest on the anniversary of the vesting condition or December 22 of the relevant year. The VWAP condition has a minimum of three potential tranches and the market capitalization award has a minimum of two potential tranches. For market-based awards, share-based compensation expense will be recognized over the longer of the expected achievement period for the relevant market condition and the service condition. The market condition period and the valuation of each tranche were determined using a Monte Carlo simulation. In the event the market condition is met prior to the expected achievement period, any then-unrecognized compensation expense associated with the options or RSUs that have vested with respect to both the market condition and the service condition will be recognized immediately in the Company’s consolidated statements of operations. Awards to the Board of Directors under the 2021 AGM Awards The Board of Director awards consist of an aggregate 68,600 options and RSUs as follows: • 41,400 o 6,900 • 27,200 1/3 o 13,600

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes At December 31, 2021, the Company and its subsidiaries had net operating loss carryforwards for federal, state, United Kingdom, and Australian income tax purposes of $122.0 million, $79.7 million, $31.9 million and $38.2 million respectively. The net operating loss carryforwards may be subject to limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions of the Internal Revenue Code and similar state and foreign provisions. Of these carryforwards, $21.7 million will expire, if not utilized, between 2026 through 2038. The state carryforwards begin to expire between 2026 through 2041. The remaining carryforwards have no expiration. The Company is forecasting current year losses and has full valuation allowances against its deferred tax assets. Tax expense for the three months ended March 31, 2022 and 2021 of $4,000 and $10,000, respectively, is related to state minimum taxes. In assessing the recoverability of its deferred tax assets, the Company considers whether it is more likely than not that its deferred assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. The Company considers all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Based upon the weight of available evidence including the uncertainty regarding the Company’s ability to utilize certain net operating losses and tax credits in the future, the Company has established a valuation allowance against its net deferred tax assets of $51.3 million and $46.9 million as of December 31, 2021 and 2020, respectively. The deferred tax assets are primarily net operating loss carryforwards for which management has determined it is more likely than not that the deferred tax assets will not be realized. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements related to a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. The Company has not identified any uncertain tax positions as of March 31, 2022 or December 31, 2021. The Company files income tax returns in the U.S. federal, California and certain other state and foreign jurisdictions. The Company remains subject to income tax examinations for its U.S. federal and state income taxes generally for fiscal years ended June 30, 2006 and forward. The Company also remains subject to income tax examinations for international income taxes for fiscal years ended June 30, 201 8 through June 30, 20 2 1 , and for certain other U.S. state and local income taxes generally for the fiscal years ended June 30, 201 8 through June 30, 202 1 .

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	17. Net Loss per Share The following is a reconciliation of the basic and diluted loss per share computations: Three months ended March 31, (in thousands, except per share data) 2022 2021 Net Loss $ (9,463 ) $ (5,997 ) Weighted-average common shares – outstanding, basic 24,938 22,734 Weighted-average common shares – outstanding, diluted 24,938 22,734 Net loss per common share, basic $ (0.38 ) $ (0.26 ) Net loss per common share, diluted $ (0.38 ) $ (0.26 ) The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. For the purposes of the calculation of diluted net loss per share, options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the three months ended March 31, 2022 and 2021, diluted net loss per common share is the same as the basic net loss per share for those periods.

Retirement Plans

Retirement Plans	3 Months Ended
	Mar. 31, 2022
Compensation And Retirement Disclosure [Abstract]
Retirement Plans	18. Retirement Plans The Company offers a 401(k)-retirement savings plan (the “401(k) Plan” Deferred compensation plans The Company’s Deferred Compensation Plan (the "DCP"), which became effective on October 2021 allows for eligible management and highly compensated key employees to elect to defer a portion of their salary, bonus, commissions and RSU awards to later years. These deferrals are immediately vested and are subject to investment risk and a risk of forfeiture under certain circumstances. The Company matches 4% to 6% (depending on level) of employee contributions. These matching employer contributions are vested over a two-year The Company established a COLI to fund the DCP. The COLI is subject to creditor claims in the event of insolvency, but the assets held in the COLI are not available for general corporate purposes. Amounts in the COLI are invested in a number of funds. The securities are carried at the cash surrender value and are included in other long-term assets on the Consolidated Balance Sheets. We record investment gains and losses in operating expenses on the Consolidated Statements of Operations, along with the offsetting amount related to the increase or decrease in deferred compensation liability. The fair values of the Company’s deferred compensation plan assets and liability are included in the table below. For additional information on the fair value hierarchy and the inputs used to measure fair value, see Note 5, Fair Value Measurements. Fair Value as of March 31, 2022 Fair Value as of December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Corporate-owned life insurance policies (1) - 586 - 586 - 304 - 304 (1) The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP SEC Transition Report There have been no changes to the Company’s significant accounting policies as described in the T ransition R eport on Form 10-K T that have had a material impact on the Company’s consolidated financial statements . See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the Transition Report.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts (including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, accounting for marketable securities, income taxes, stock-based compensation, and the stand-alone selling price for the BARDA contract) and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The financial position and results of operations of the Company’s operating non-U.S. subsidiaries are generally determined using the respective local currency as the functional currency of that subsidiary. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each period end. Income statement accounts are translated at the average rate of exchange prevailing during the period. Adjustments arising from the use of differing exchange rates from period to period are included in accumulated other comprehensive gain (loss) in shareholders’ equity. Gains and losses resulting from foreign currency transactions are included in general and administrative expenses and were a loss of $22,000 and gain of $8,000 for the three months ended March 31, 2022 and 2021, respectively. The Company’s non-operating subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period and nonmonetary assets and liabilities at historical rates. Gains and losses resulting from these remeasurements and foreign currency transactions are included in general and administrative expenses. During the three months ended March 31, 2022 and 2021, the Company recorded losses of $15,000 and $16,000, respectively.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The components of comprehensive income (loss) consist of net income (loss), foreign currency translation adjustments from its subsidiaries not using the U.S. dollar as their functional currency and unrealized gains and losses in investments available for sale. The Company did not have reclassifications from other comprehensive income (loss) to net loss during the quarter ended March 31, 2022.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Accounting Standard Codification (“ASC”) Topic 606, Revenue Recognition, the Company performs the following five steps: 1. Identify the contract with a customer 2. Identify the performance obligations 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations 5. Recognize revenue when/as performance obligation(s) are satisfied In order for an arrangement to be considered a contract, it must be probable that the Company will collect the consideration to which it is entitled for goods or services to be transferred. Once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised with each contract, determines whether those are performance obligations and the related transaction price. The Company then recognizes the sale of goods based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company’s revenue consists primarily of the sale of the RECELL System to hospitals or other treatment centers and to BARDA (collectively, “customers”), predominately in the United States. The Company evaluated the BARDA contract and concluded that a portion of the arrangement, such as the procurement of the RECELL system and the emergency preparedness, represents a transaction with a customer and as such are in the scope of ASC 606. Amounts received from BARDA for the research and development of the Company’s product are classified as BARDA income in the consolidated statement of operations and are accounted for under IAS 20. For further details refer to BARDA Income and Receivables below. Revenues for commercial customers (hospitals and treatment centers) are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. For the Company’s contracts that have an original duration of one year or less, the Company elected the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred. For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services. Through this contract the Company promises to procure the product through a vendor management inventory arrangement and to stand ready to provide emergency deployment services related to the product. Emergency preparedness services include procuring necessary storage containers, housing, and maintaining the containers (and product), and providing shipping and handling services in the event of an emergency situation. This stand ready obligation is a series of distinct services that are substantially the same and have the same pattern of transfer to the customer, overtime as services are consumed. The total transaction price for the portion of the BARDA contract that is within the scope of ASC 606, was determined to be $9.2 million. The transaction price was allocated on a stand-alone selling price basis as follows: $7.6 million to the procurement of the RECELL product, which is classified as revenues when recognized in the consolidated statement of operations and $1.6 million to the emergency deployment services which is classified as revenues when recognized in the consolidated statement of operations. The $1.6 million for emergency deployment includes variable consideration which is deemed immaterial to the contract as a whole. The Company estimated the stand-alone selling price of the procurement of the RECELL product based on historical pricing of the Company’s product at the initial execution of the contract. The Company estimated the stand-alone selling price of the emergency deployment services performed based on the Company’s projected cost of providing the services plus an applicable profit margin as denoted in the contract. The Company’s performance obligations are either satisfied at a point in time or over time as services are provided. Securities and Exchange Commission (SEC) Interpretation, Commission Guidance regarding Accounting for Sale of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile (SNS).
Contract Liabilities	Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 days, and do not include a financing component. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer.
Cost of Sales	Cost of Sales Cost of sales related to products includes costs to manufacture or purchase, package, and ship the Company’s products. Costs also include relevant production overhead and depreciation and amortization. These costs are recognized when control of the product is transferred to the customer and revenue is recognized.
Income Taxes	Income Taxes Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet. The Company reviews its uncertain tax positions regularly. An uncertain tax position represents the Company’s expected treatment of a tax position taken in a filed return or planned to be taken in a future tax return or claim that has not been reflected in measuring income tax expense for financial reporting purposes. The Company recognizes the tax benefit from an uncertain tax position when it is more-likely-than-not that the position will be sustained upon examination on the basis of the technical merits or the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired.
Cash and Cash Equivalents	Cash and Cash Equivalents Consists of cash held at deposit institutions and cash equivalents. Cash equivalents consist of short-term highly liquid investments with original maturities of three months or less from the date of purchase and consist primarily of money market funds. The Company holds cash at deposit institutions in the amount of $6.9 million and $4.4 million of which $760,000 and $203,000 is denominated in foreign currencies in foreign institutions as of March 31, 2022 and December 31, 2021, respectively. As of March 31, 2022 and December 31, 2021, the Company held cash equivalents in the amount of $16.6 million and $51.1 million, respectively.
Restricted Cash	Restricted Cash Pursuant to a contractual agreement to maintain the business credit card, the Company must maintain restricted cash deposits which amounted to approximately $201,000 and $201,000 as of March 31, 2022 and December 31, 2021, respectively.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, BARDA receivables and other receivables. As of March 31, 2022 and December 31, 2021, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of March 31, 2022 no single commercial customer accounted for more than 10% of total revenues or net accounts receivable. BARDA revenue for emergency deployment accounted for approximately 1% and 47% of total revenues for the three months ended March 31, 2022 and 2021, respectively. BARDA receivables for emergency preparedness services accounted for 1% and 3% of total BARDA receivables as of March 31, 2022 and December 31, 2021, respectively. See table below for breakdown of BARDA receivables (in thousands). As of March 31, 2022 As of December 31, 2021 BARDA procurement and emergency preparedness services $ 8 $ 9 BARDA expense reimbursements 674 299 Total BARDA receivables $ 682 $ 308
Marketable Securities	Marketable Securities We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date. Classification is determined at the time of purchase and re-evaluated each balance sheet date. Short-term marketable securities represent investment of cash available for current operations. We account for our marketable securities as available-for-sale securities. All marketable securities, which consist of corporate debt securities, U.S government agency obligations, U.S treasury and commercial paper are denominated in the U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders equity until realized. Realized gains and losses on marketable securities are included in other income in the accompanying Consolidated Statements of Operations. The cost of any marketable securities sold is based on the specific identification method. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable securities is included in other income. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the maximum final maturity from the date of purchase is thirty-seven months. If necessary, the Company will recognize an allowance for credit losses on available-for-sale debt securities on an individual basis, and will no longer consider other than-temporary impairment or immediately reduce the cost basis of the investment provided that it is more likely than not that the security will be held to recovery or maturity. Further, the Company will recognize any improvements in estimated credit losses on available-for-sale debt securities immediately in earnings and reduce the existing allowance for credit losses. The Company will disaggregate its available-for-sale debt securities into the following categories: commercial paper, corporate debt, government and agency securities and money market funds. The Company’s corporate bonds are comprised of predominantly high-grade corporate bonds while its government and agency securities are U.S. treasury bonds, and U.S. agency bonds. The Company has analyzed both corporate bonds and government and agency securities and identified that both types of securities have similar risk characteristics in that they are traded infrequently and have contractual interest rates and maturity dates. To evaluate for impairment, management reviews credit rating changes, securities trends, interest rate movements and unrealized loss at the security level of the Company’s available for sale debt securities. If any of these give rise to a potential credit concern, the Company performs a discounted cash flow analysis to determine the credit portion of the impairment. The discounted cash flow analysis will be performed either internally or through the assistance of a qualified third party. Once the credit component of the impairment is determined, the Company will record the impaired amount as an allowance to the available-for-sale debt securities balance and as a charge to other income in the accompanying Consolidated Statements of Operations, not to exceed the amount of the unrealized loss. The Company assesses expected credit losses at the end of each reporting period and adjusts the allowance through other income.
BARDA Income and Receivables	BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs and a fixed-fee earned. Billings under the contracts are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, general and administrative expenses and a fixed fee. The Company has concluded that grants under the BARDA arrangement are not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition Accounting for Government Grants and Disclosure of Government Assistance,
Leases	Leases The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company’s operating leases have remaining lease terms of one year to two years, some of which include options to renew the lease. At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. Right of use (“ ROU IBR The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. Lease expense is recognized on a straight-line basis over the lease term and is primarily included in general and administrative expenses in the accompanying consolidated statements of operations. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all underlying asset classes. Some leases require variable payments for common area maintenance, property taxes, parking, insurance and other variable costs. The variable portion of lease payments is not included in operating lease assets or liabilities. Variable lease costs are expensed when incurred.
Share-based Compensation	Share-based compensation The Company records compensation expense for stock options based on the fair market value of the awards on the date of grant. The fair value of share-based compensation awards is amortized over the vesting period of the award. Compensation expense for performance-based awards is measured based on the number of shares ultimately expected to vest, estimated at each reporting date based on management’s expectations regarding the relevant performance criteria, if any. The Black-Scholes option pricing model and Monte Carlo Simulation were used to estimate the fair value of the time-based and performance-based options, respectively. Under ASU 2016-09, Compensation – Stock Compensation (“ASC 718”) Improvements to Employee Share-Based Payment Accounting The following assumptions were used in the valuation of stock options. • Expected volatility – determined using the average of the historical volatility using daily intervals over the expected term and the derived volatility using the longest term available of 12 months. • Expected dividends - based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future • Expected term – the expected term of the Company’s stock options for tenure only vesting has been determined utilizing the “simplified” method as described in the SEC’s Staff Accounting Bulletin No. 107 relating to share-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history of awards granted, the first plan was established in 2016 and was primarily used for Executives awards. Further, the Company does not have sufficient history of exercises in the U.S. market given the recent redomiciliation to the United States during 2020. The expected term of options with a performance condition was set to the contractual term of 10 years. • Risk-free interest rate – t he risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award.
Segment Reporting	Segment Reporting Operating segments are defined as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as one segment.
Deferred Compensation Plan and Investments in Corporate-Owned Life Insurance	Deferred Compensation Plan and Investments in Corporate-Owned Life Insurance The Company’s Deferred Compensation Plan (the " DCP Compensation – Retirement Benefits two-years accounted for as compensation expense with a corresponding adjustment to deferred compensation liability. Upon distribution, the Company will record the distribution as a decrease to compensation liability with corresponding credit to cash. The Company funds the DCP through a Corporate-Owned Life Insurance ( COLI ). Per the ASC 325-30-25-1A , Investments – Other , COLI is recorded as an asset in ther ong- erm assets as it does not meet the definition of a plan asset under ASC 715. COLI

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Other Receivables	See table below for breakdown of BARDA receivables (in thousands). As of March 31, 2022 As of December 31, 2021 BARDA procurement and emergency preparedness services $ 8 $ 9 BARDA expense reimbursements 674 299 Total BARDA receivables $ 682 $ 308

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Available For Sale Securities [Abstract]
Summary of Amortized Cost and Estimates Fair Values of Debt Securities Available for Sale	The following table summarizes the amortized cost and estimates fair values of debt securities available for sale: March 31, 2022 Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Carrying Value (in thousands) Cash Equivalents: Money market funds $ 16,617 $ - $ - $ 16,617 Current marketable securities: U.S Treasury securities $ 27,246 $ 1 $ (114 ) $ 27,133 Commercial paper 21,331 - - 21,331 Corporate debt securities 9,517 1 (43 ) 9,475 U.S Government Agency Obligations 1,906 - (10 ) 1,896 Total current marketable securities $ 60,000 $ 2 $ (167 ) $ 59,835 Long-term marketable securities: U.S Treasury securities $ 10,990 $ - $ (234 ) $ 10,756 Corporate debt securities 931 - (3 ) 928 Total Long-term marketable securities $ 11,921 $ - $ (237 ) $ 11,684 As of December 31, 2021 Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Carrying Value (in thousands) Cash Equivalents: Money market funds $ 51,112 $ - $ - $ 51,112 Current marketable securities: Commercial paper $ 19,586 $ - $ - $ 19,586 Corporate debt securities 7,068 - (7 ) 7,061 Asset-backed securities 3,002 - - 3,002 Total current marketable securities $ 29,656 $ - $ (7 ) $ 29,649 Long-term marketable securities: U.S Treasury securities $ 18,043 $ - $ (89 ) $ 17,954 Corporate debt securities 1,746 - (8 ) 1,738 Total Long-term marketable securities $ 19,789 $ - $ (97 ) $ 19,692
Summary of Maturities of Debt Securities Available for Sale	The maturities of debt securities available for sale are summarized in the following table using contractual maturities. Actual maturities may differ from contractual maturities due to obligations that are called or prepaid. As of March 31, 2022 As of December 31, 2021 Amortized Cost Carrying Value Amortized Cost Carrying Value Due in one year or less 60,000 59,835 $ 29,656 $ 29,649 Due after one year through three years 11,921 11,684 $ 19,789 $ 19,692

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: As of March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash Equivalents Money market funds $ 16,617 $ - $ - $ 16,617 Total cash equivalents 16,617 - - 16,617 Short-term marketable securities U.S Treasury securities - 27,133 - 27,133 Commercial paper - 21,331 - 21,331 Corporate debt securities - 9,475 - 9,475 U.S Government Agency Obligations - 1,896 - 1,896 Total short-term marketable securities - 59,835 - 59,835 Long-term investments U.S Treasury securities - 10,756 - 10,756 Corporate debt securities - 928 - 928 Total long-term marketable securities - 11,684 - 11,684 Total marketable securities and cash equivalents $ 16,617 $ 71,519 $ - $ 88,136 As of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Cash Equivalents Money market funds $ 51,112 $ - $ - $ 51,112 Total cash equivalents 51,112 - - 51,112 Short-term marketable securities Commercial paper - 19,586 - 19,586 Asset-backed securities - 3,002 - 3,002 Corporate debt securities - 7,061 - 7,061 Total short-term marketable securities - 29,649 - 29,649 Long-term investments U.S Treasury securities - 17,954 - 17,954 Corporate debt securities - 1,738 - 1,738 Total long-term marketable securities - 19,692 - 19,692 Total marketable securities and cash equivalents $ 51,112 $ 49,341 $ - $ 100,453

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary Of Lease Cost	The following table sets forth the Company’s operating lease expenses which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Three months ended March 31, 2022 2021 Operating lease cost $ 194 $ 186 Variable lease cost 13 12 Total lease cost $ 207 $ 198
Summary Of Supplemental Cash Flow Information Related To Operating Leases	Supplemental cash flow information related to operating leases for the three months ended March 31, 2022 and 2021 was as follows (in thousands): Three months ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 198 $ 191
Summary Of Supplemental Balance Sheet Information Related To Operating Leases	Supplemental balance sheet information, as of March 31, 2022 and December 31, 2021 related to operating leases was as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Reported as: Operating lease right-of-use assets $ 1,375 $ 1,544 Total right-of-use assets $ 1,375 $ 1,544 Other current liabilities: Operating lease liabilities, short-term $ 738 $ 720 Operating lease liabilities, long term 726 918 Total operating lease liabilities $ 1,464 $ 1,638 Operating lease weighted average remaining lease term (years) 2.07 2.30 Operating lease weighted average discount rate 6.54 % 6.51 %
Summary Of Maturities Of The Company's Operating Lease Liabilities	As of March 31, 2022, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases 2022 $ 604 2023 649 2024 313 2025 - Total lease payments 1,566 Less imputed interest (102 ) Total operating lease liabilities $ 1,464

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Summary Of Composition Of Inventory	The composition of inventory is as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Raw materials $ 1,256 $ 1,222 Work in process 439 176 Finished goods 108 734 Total inventory $ 1,803 $ 2,132

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill And Intangible Assets Disclosure [Abstract]
Summary Of Composition Of Intangible Assets	The composition of intangible assets, net is as follows (in thousands): As of March 31, 2022 As of December 31, 2021 Weighted Average Life Gross Amount Accumulated Amortization Net Carry Amount Gross Amount Accumulated Amortization Net Carry Amount Patent 1 2 $ 211 $ (210 ) $ 1 $ 209 $ (182 ) $ 27 Patent 2 11 128 (19 ) 109 123 (18 ) 105 Patent 3 14 192 (28 ) 164 192 (25 ) 167 Patent 5 20 46 (4 ) 42 46 (3 ) 43 Patent 6 20 39 (3 ) 36 39 (2 ) 37 Patent 7 13 2 - 2 2 - 2 Patent 8 20 3 - 3 3 - 3 Patent 10 19 3 - 3 3 - 3 Patent 11 19 6 - 6 6 - 6 Trademarks Indefinite 50 - 50 50 - 50 Total intangible assets $ 680 $ (264 ) $ 416 $ 673 $ (230 ) $ 443
Summary Of Future Amortization Of Amortizable Intangible Assets Held	The Company expects the future amortization of amortizable intangible assets held at March 31, 2022 to be (in thousands) Estimated Amortization Expense 2023 30 2024 30 2025 30 2026 30 2027 30 Thereafter 216 Total $ 366

Plant and Equipment (Tables)

Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Summary of Composition of Property, Plant and Equipment	The composition of property, plant and equipment, net is as follows (in thousands): Useful Lives As of March 31, 2022 As of December 31, 2021 Computer equipment 3 years $ 750 $ 740 Computer software 3 years 811 811 Construction in progress - 29 Furniture and fixtures 7 years 440 440 Laboratory equipment 5 years 623 566 Leasehold improvements Lesser of life or lease term 242 242 RECELL Moulds 5 years 129 129 Less: accumulated amortization and depreciation (1,824 ) (1,695 ) Total plant and equipment, net $ 1,171 $ 1,262

Prepaids and Other Current As_2

Prepaids and Other Current Assets and Other Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaids And Other Current Assets And Other Long Term Assets [Abstract]
Summary of Prepaids and Other Current Assets	Prepaids and other current assets consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2021 Prepaid expenses $ 994 $ 1,124 Lease deposits 2 2 Accrued investment income 123 72 Other receivables 27 15 Total prepaids and other current assets $ 1,146 $ 1,213
Summary of Other Long Term Assets	Other long-term assets consisted of the following (in thousands): As of March 31, 2022 As of December 31, 2021 BARDA contract costs $ 441 $ 504 Corporate-owned life insurance policies 586 304 Long-term lease deposits 124 124 Long-term prepaids 11 10 Total other long-term assets $ 1,162 $ 942

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule Of Revenue and Cost Of Sales By Region and Customer Type	Revenue by region for the three months ended March 31, 2022 and 2021 were as follows (in thousands): Three months ended March 31, 2022 2021 Revenue: United States $ 7,398 $ 8,725 Foreign: Australia 87 25 United Kingdom 54 15 Total $ 7,539 $ 8,765 Revenue and Cost of sales by Customer type for the three months ended March 31, 2022 and 2021 were as follows (in thousands): Three months ended March 31, 2022 2021 Revenue: Commercial sales $ 7,446 $ 4,622 BARDA: Product sales - 4,085 Services for emergency preparedness 93 58 Total $ 7,539 $ 8,765 Three months ended March 31, 2022 2021 Cost of sales Commercial cost $ 1,705 $ 966 BARDA: Product cost (12 ) 1,130 Emergency preparedness service cost 85 50 Total $ 1,778 $ 2,146

Share-Based Payment Plans (Tabl

Share-Based Payment Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary Of Stock-based Compensation Is Reflected In The Statements Of Operations	The Company has included share-based compensation expense as part of operating expenses in the accompanying consolidated statements of operations as follows (in thousands): Three-months ended March 31, 2022 2021 Sales and marketing expenses $ 329 $ 238 General and administrative expenses 2,327 930 Research and development expenses 276 165 Total $ 2,932 $ 1,333
Summary Of Share Option Activity	A summary of share option activity as of March 31, 2022 and changes during the period ended is presented below: Service Only Share Options Performance Based Share Options Market Awards Total Share Options Outstanding shares at December 31, 2021 1,129,126 599,994 27,600 1,756,720 Granted 21,900 - - 21,900 Exercised (125 ) - - (125 ) Expired (2,275 ) - - (2,275 ) Forfeited (5,050 ) - - (5,050 ) Outstanding shares at March 31, 2022 1,143,576 599,994 27,600 1,771,170 Exercisable at March 31, 2022 592,085 319,219 - 911,304
Non Option Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary Of Share Option Activity	A summary of the status of the Company’s unvested RSUs as of March 31, 2022, and changes that occurred during the year is presented below: Service Condition RSU Performance Condition RSU Market Condition Total RSU's Unvested RSUs outstanding at December 31, 2021 114,757 135,093 47,640 297,490 Vested - (29,713 ) - (29,713 ) Unvested RSUs outstanding at March 31, 2022 114,757 105,380 47,640 267,777

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary Of Reconciliation Of The Basic And Diluted Loss Per Share	The following is a reconciliation of the basic and diluted loss per share computations: Three months ended March 31, (in thousands, except per share data) 2022 2021 Net Loss $ (9,463 ) $ (5,997 ) Weighted-average common shares – outstanding, basic 24,938 22,734 Weighted-average common shares – outstanding, diluted 24,938 22,734 Net loss per common share, basic $ (0.38 ) $ (0.26 ) Net loss per common share, diluted $ (0.38 ) $ (0.26 )

Retirement Plans (Tables)

Retirement Plans (Tables)	3 Months Ended
	Mar. 31, 2022
Compensation And Retirement Disclosure [Abstract]
Summary of Fair Values of Company's Deferred Compensation Plan Assets and Liability	The fair values of the Company’s deferred compensation plan assets and liability are included in the table below. For additional information on the fair value hierarchy and the inputs used to measure fair value, see Note 5, Fair Value Measurements. Fair Value as of March 31, 2022 Fair Value as of December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Corporate-owned life insurance policies (1) - 586 - 586 - 304 - 304 (1) The corporate-owned life insurance contracts are recorded at cash surrender value, which is provided by a third party and reflects the net asset value of the underlying publicly traded mutual funds and are categorized as Level 2.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Mar. 31, 2022USD ($)PerformanceObligationSegment	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions	$ (37,000)	$ (8,000)
Contract description	For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services.
Cash at deposit institutions	$ 6,900,000		$ 4,400,000
Cash in foreign institutions	760,000		203,000
Cash equivalents held	16,600,000		51,100,000
Restricted cash	$ 201,000		$ 201,000
Concentration risk, customer	no
Description of maturity terms	We classify all highly liquid investments with original maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. The Company classifies marketable securities as short-term when they have remaining contractual maturities of one year or less from the balance sheet date, and as long-term when the investments have remaining contractual maturities of more than one year from the balance sheet date
Final maturity period	37 months
Lease renewal period	3 years
Contractual term	10 years
Number of business segment | Segment	1
Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting period	2 years
Vesting on Year One | Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting percentage	25.00%
Vesting on Year Two | Deferred Compensation Plans
Summary Of Significant Accounting Policies [Line Items]
Employer matching contributions, Vesting percentage	75.00%
Accounts Receivable | Customer Concentration Risk | Commercial Customer
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%
Minimum
Summary Of Significant Accounting Policies [Line Items]
Revenue, performance obligation, description of payment terms	30 days
Remaining lease terms	1 year
Maximum
Summary Of Significant Accounting Policies [Line Items]
Revenue, performance obligation, description of payment terms	90 days
Remaining lease terms	2 years
BARDA
Summary Of Significant Accounting Policies [Line Items]
Number of performance obligations | PerformanceObligation	2
Total transaction price of contract	$ 9,200,000
RECELL system | BARDA
Summary Of Significant Accounting Policies [Line Items]
Number of units will be delivered	5,614
Transaction price allocated on a stand alone selling price basis	$ 7,600,000
Emergency Deployment | BARDA
Summary Of Significant Accounting Policies [Line Items]
Transaction price allocated on a stand alone selling price basis	$ 1,600,000
Emergency Deployment Service | Revenue Benchmark | Customer Concentration Risk | Commercial Customer
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	1.00%	47.00%
Emergency Preparedness Services | BARDA | Accounts Receivable Revenue | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	1.00%		3.00%
General and Administrative Expense
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions	$ (15,000)	$ (16,000)
General and Administrative Expense | Non-US
Summary Of Significant Accounting Policies [Line Items]
Gain (loss) on foreign currency transactions	(22,000)	$ 8,000
Revenue | RECELL system | BARDA
Summary Of Significant Accounting Policies [Line Items]
Transaction price allocated on a stand alone selling price basis	$ 1,600,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Other Receivables (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Receivables Net Current [Abstract]
BARDA procurement and emergency preparedness services	$ 8	$ 9
BARDA expense reimbursements	674	299
Total BARDA receivables	$ 682	$ 308

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimates Fair Values of Debt Securities Available for Sale (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	$ 60,000	$ 29,656
Gross Unrealized Holding Gains, Current marketable securities	2
Gross Unrealized Holding Losses, Current marketable securities	(167)	(7)
Carrying Value, Current marketable securities	59,835	29,649
Amortized Cost, Long-term marketable securities	11,921	19,789
Gross Unrealized Holding Losses, Long-term marketable securities	(237)	(97)
Carrying Value, Long-term marketable securities	11,684	19,692
Cash Equivalents | Money Market Funds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	16,617	51,112
Carrying Value	16,617	51,112
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	21,331	19,586
Carrying Value, Current marketable securities	21,331	19,586
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	9,517	7,068
Gross Unrealized Holding Gains, Current marketable securities	1
Gross Unrealized Holding Losses, Current marketable securities	(43)	(7)
Carrying Value, Current marketable securities	9,475	7,061
Amortized Cost, Long-term marketable securities	931	1,746
Gross Unrealized Holding Losses, Long-term marketable securities	(3)	(8)
Carrying Value, Long-term marketable securities	928	1,738
U.S Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	27,246
Gross Unrealized Holding Gains, Current marketable securities	1
Gross Unrealized Holding Losses, Current marketable securities	(114)
Carrying Value, Current marketable securities	27,133
Amortized Cost, Long-term marketable securities	10,990	18,043
Gross Unrealized Holding Losses, Long-term marketable securities	(234)	(89)
Carrying Value, Long-term marketable securities	10,756	17,954
U.S Government Agency Obligations
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities	1,906
Gross Unrealized Holding Losses, Current marketable securities	(10)
Carrying Value, Current marketable securities	$ 1,896
Asset-backed Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost, Current marketable securities		3,002
Carrying Value, Current marketable securities		$ 3,002

Marketable Securities - Summa_2

Marketable Securities - Summary of Maturities of Debt Securities Available for Sale (Detail) - Contractual Maturities - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Available for sale securities, Due in one year or less, Amortized cost	$ 60,000	$ 29,656
Due after one year through three years	11,921	19,789
Available for sale securities, Due in one year or less, Carrying value	59,835	29,649
Due after one year through three years	$ 11,684	$ 19,692

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Unrealized gain on marketable securities	$ 2,000	$ 0
Unrealized loss on marketable securities	404,000	104,000
Net unrealized loss on marketable securities	402,000	104,000
Credit loss recognized	0	0
Prepaids and Other Current Assets
Schedule Of Available For Sale Securities [Line Items]
Accrued interest income	$ 123,000	$ 72,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	$ 59,835	$ 29,649
Total long-term marketable securities	11,684	19,692
Fair Value on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	16,617	51,112
Total short-term marketable securities	59,835	29,649
Total long-term marketable securities	11,684	19,692
Total marketable securities and cash equivalents	88,136	100,453
Fair Value on Recurring Basis | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	16,617	51,112
Total marketable securities and cash equivalents	16,617	51,112
Fair Value on Recurring Basis | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	59,835	29,649
Total long-term marketable securities	11,684	19,692
Total marketable securities and cash equivalents	71,519	49,341
Fair Value on Recurring Basis | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	16,617	51,112
Fair Value on Recurring Basis | Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	16,617	51,112
Fair Value on Recurring Basis | Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	21,331	19,586
Fair Value on Recurring Basis | Commercial Paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	21,331	19,586
Fair Value on Recurring Basis | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	9,475	7,061
Total long-term marketable securities	928	1,738
Fair Value on Recurring Basis | Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	9,475	7,061
Total long-term marketable securities	928	1,738
Fair Value on Recurring Basis | U.S Government Agency Obligations
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	1,896
Fair Value on Recurring Basis | U.S Government Agency Obligations | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	1,896
Fair Value on Recurring Basis | U.S Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	27,133
Total long-term marketable securities	10,756	17,954
Fair Value on Recurring Basis | U.S Treasury Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities	27,133
Total long-term marketable securities	$ 10,756	17,954
Fair Value on Recurring Basis | Asset-backed Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities		3,002
Fair Value on Recurring Basis | Asset-backed Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total short-term marketable securities		$ 3,002

Leases - Additional Information

Leases - Additional Information (Detail)	Aug. 31, 2021USD ($)
Leases [Abstract]
Increase in operating lease ROU assets and operating lease liabilities	$ 392,000

Leases - Summary Of Lease Cost

Leases - Summary Of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lease Cost [Abstract]
Operating lease cost	$ 194	$ 186
Variable lease cost	13	12
Total lease cost	$ 207	$ 198

Leases - Summary Of Supplementa

Leases - Summary Of Supplemental Cash Flow Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disclosure Of Supplemental Cash Flow Information Related To Operating Leases [Abstract]
Operating cash outflows from operating leases	$ 198	$ 191

Leases - Summary Of Supplemen_2

Leases - Summary Of Supplemental Balance Sheet Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Disclosure Of Supplemental Balance Sheet Information Related To Operating Leases [Abstract]
Operating lease right-of-use assets	$ 1,375	$ 1,544
Total right-of-use assets	1,375	1,544
Operating lease liabilities, short-term	$ 738	$ 720
Operating Lease Liability Current Statement Of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Operating lease liabilities, long-term	$ 726	$ 918
Total operating lease liabilities	$ 1,464	$ 1,638
Operating lease weighted average remaining lease term (years)	2 years 25 days	2 years 3 months 18 days
Operating lease weighted average discount rate	6.54%	6.51%

Leases - Summary Of Maturities

Leases - Summary Of Maturities Of The Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating Lease Liabilities Payments Due [Abstract]
2022	$ 604
2023	649
2024	313
Total lease payments	1,566
Less imputed interest	(102)
Total operating lease liabilities	$ 1,464	$ 1,638

Inventory - Summary Of Composit

Inventory - Summary Of Composition Of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,256	$ 1,222
Work in process	439	176
Finished goods	108	734
Total inventory	$ 1,803	$ 2,132

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventory impairments	$ 97,000	$ 243,000

Intangible Assets - Summary Of

Intangible Assets - Summary Of Composition Of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 680	$ 673
Finite Lived Intangible Assets, Accumulated Amortization	(264)	(230)
Finite Lived Intangible Assets, Net Carrying Amount	366
Intangible Assets, Net (Excluding Goodwill)	416	443
Trademarks
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 50	50
Patent 1
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years
Finite Lived Intangible Assets, Gross Amount	$ 211	209
Finite Lived Intangible Assets, Accumulated Amortization	(210)	(182)
Finite Lived Intangible Assets, Net Carrying Amount	$ 1	27
Patent 2
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	11 years
Finite Lived Intangible Assets, Gross Amount	$ 128	123
Finite Lived Intangible Assets, Accumulated Amortization	(19)	(18)
Finite Lived Intangible Assets, Net Carrying Amount	$ 109	105
Patent 3
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite Lived Intangible Assets, Gross Amount	$ 192	192
Finite Lived Intangible Assets, Accumulated Amortization	(28)	(25)
Finite Lived Intangible Assets, Net Carrying Amount	$ 164	167
Patent 5
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 46	46
Finite Lived Intangible Assets, Accumulated Amortization	(4)	(3)
Finite Lived Intangible Assets, Net Carrying Amount	$ 42	43
Patent 6
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 39	39
Finite Lived Intangible Assets, Accumulated Amortization	(3)	(2)
Finite Lived Intangible Assets, Net Carrying Amount	$ 36	37
Patent 7
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years
Finite Lived Intangible Assets, Gross Amount	$ 2	2
Finite Lived Intangible Assets, Net Carrying Amount	$ 2	2
Patent 8
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 3	3
Finite Lived Intangible Assets, Net Carrying Amount	$ 3	3
Patent 10
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 3	3
Finite Lived Intangible Assets, Net Carrying Amount	$ 3	3
Patent 11
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Finite Lived Intangible Assets, Gross Amount	$ 6	6
Finite Lived Intangible Assets, Net Carrying Amount	$ 6	$ 6

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment of intangible assets	$ 0	$ 0
Amortization of intangible assets	$ 34,000	$ 30,000

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization of Amortizable Intangible assets held (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2023	$ 30
2024	30
2025	30
2026	30
2027	30
Thereafter	216
Finite Lived Intangible Assets, Net Carrying Amount	$ 366

Plant and Equipment - Summary O

Plant and Equipment - Summary Of Composition Of Property, Plant And Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Less: accumulated amortization and depreciation	$ (1,824)	$ (1,695)
Total plant and equipment, net	$ 1,171	1,262
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 750	740
Computer Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 811	811
Construction In Progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		29
Furniture And Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 440	440
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 623	566
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Useful Lives	Lesser of life or lease term
Property, Plant and Equipment, Gross	$ 242	242
RECELL Moulds
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 129	$ 129

Plant and Equipment - Additiona

Plant and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property Plant And Equipment [Abstract]
Depreciation	$ 129,000	$ 137,000

Prepaids and Other Current As_3

Prepaids and Other Current Assets and Other Long-Term Assets - Summary of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaids And Other Current Assets And Other Long Term Assets [Abstract]
Prepaid expenses	$ 994	$ 1,124
Lease deposits	2	2
Accrued investment income	123	72
Other receivables	27	15
Total prepaids and other current assets	$ 1,146	$ 1,213

Prepaids and Other Current As_4

Prepaids and Other Current Assets and Other Long-Term Assets - Summary of Other Long Term Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Assets Noncurrent Disclosure [Abstract]
BARDA contract costs	$ 441	$ 504
Corporate-owned life insurance policies	586	304
Long-term lease deposits	124	124
Long-term prepaids	11	10
Total other long-term assets	$ 1,162	$ 942

Reporting Segment and Geograp_3

Reporting Segment and Geographic Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022Segment
Segment Reporting [Abstract]
Number of reporting segment	1

Reporting Segment and Geograp_4

Reporting Segment and Geographic Information - Schedule Of Revenue and Cost Of Sales By Region and Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenues	$ 7,539	$ 8,765
Cost of sales
Cost of sales	1,778	2,146
BARDA deferred costs	12	198
Commercial Sales
Revenue:
Revenues	7,446	4,622
Product Sales
Revenue:
Revenues		4,085
Services For Emergency Preparedness
Revenue:
Revenues	93	58
Commercial Cost
Cost of sales
Cost of sales	1,705	966
Product Cost
Cost of sales
BARDA deferred costs	(12)	1,130
Emergency Preparedness Service Cost
Cost of sales
BARDA deferred costs	85	50
United States
Revenue:
Revenues	7,398	8,725
Foreign | Australia
Revenue:
Revenues	87	25
Foreign | United Kingdom
Revenue:
Revenues	$ 54	$ 15

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Threatened Litigation
Litigation liability	$ 0	$ 0

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock shares authorized	200,000,000	200,000,000
Common stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock par value	$ 0.0001	$ 0.0001
Common stock shares issued	24,955,581	24,925,743
Common stock shares outstanding	24,955,581	24,925,743
Preferred stock shares outstanding	0	0
Shareholders Of Avita Medical | ADRS
Class Of Stock [Line Items]
Reverse stock split ratio, description	One share of common stock on NASDAQ is equivalent to five CDIs on the ASX.

Revenues - Additional Informati

Revenues - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022USD ($)PerformanceObligation	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract description	For revenues related to the BARDA contract within the scope of ASC 606, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units, (ii) emergency preparedness services.
Capiitalized fulfilment costs	$ 441,000		$ 504,000
Performance obligation estimated revenue expected to be recognised	882,000		952,000
Contract with customer assets	0		0
Contract with customers non current liability	882,000		952,000
Contract with customer liability revenue recognized	93,000	$ 58,000
Contract cost amortization	85,000	50,000
Contract cost impairment loss	0	0
Cost of Sales
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract cost amortization	85,000	50,000
Other Noncurrent Assets
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Capiitalized fulfilment costs	$ 441,000		504,000
BARDA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract description	For the contract with BARDA, the Company identified two performance obligations (i) the procurement of 5,614 RECELL units; and (ii) emergency preparedness services.
Number of performance obligations | PerformanceObligation	2
BARDA | RECELL system
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Number of units will be delivered	5,614
Product replacement obligation cost	$ 0
Deferred cost	52,000		64,000
Services recognised	93,000	$ 58,000
Performance obligation estimated revenue expected to be recognised	447,000		517,000
Japanese Pharmaceuticals and Medical Device Act Approval | RECELL system
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation estimated revenue expected to be recognised	$ 435,000		$ 435,000

Share-Based Payment Plans - Add

Share-Based Payment Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 22, 2021	Jun. 30, 2020	Nov. 30, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Oct. 14, 2021	Jun. 30, 2021	Nov. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation				$ 2,932	$ 1,333
Income tax benefit (expense)				$ 0	$ 0
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				267,777		297,490
Milestone performance awards to CEO				1,771,170		1,756,720
Milestone performance awards to CEO, vested				29,713
Performance Based Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO				599,994		599,994
Non Option Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				105,380		135,093
Milestone performance awards to CEO, vested				29,713
Market Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO				27,600		27,600
Non Option Market Condition
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				47,640		47,640
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement contractual term of awards				10 years
Share based compensation by share based payment arrangement vesting period				4 years
2020 Plan | Vesting Period One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage				25.00%
2020 Plan | Vesting Period Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage				25.00%
2020 Plan | Vesting Period Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage				25.00%
2020 Plan | Vesting Period Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage				25.00%
2020 Plan | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement number of shares authorised for issuance									1,750,000
Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Reverse stock split				reverse stock split of 100:1
Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement contractual term of awards				10 years
Long Term Incentive Plan | Restricted Stock Units (RSUs) | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period			395,542
Long Term Incentive Plan | Restricted Stock Units (RSUs) | Chief Executive Officer | Service Based Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period		3 years
Tenure RSU awards to CEO		142,521
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number				47,507
Long Term Incentive Plan | Restricted Stock Units (RSUs) | Chief Executive Officer | Patient Visit For Treatment And Regulatory Approval
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO on Nov 2019								253,021
2021 AGM Awards | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage	25.00%
Aggregate number of options and RSU	150,480
Tenure awards to CEO	37,600
Tenure option awards to CEO	13,800
2021 AGM Awards | Restricted Stock Units (RSUs) | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to CEO	23,800
2021 AGM Awards | Performance Based Share Options | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	37,640
Milestone performance awards to CEO	13,800
2021 AGM Awards | Performance Based Share Options | Chief Executive Officer | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	9,410
Milestone performance awards to CEO	3,450
Milestone performance awards to CEO, vested				9,410
Milestone performance awards to CEO, vested				3,450
Description of the milestone to be achieved for vesting of restricted stock awards	9,410 awards (5,960 RSUs and 3,450 options) - Achieve Centers for Medicare and Medicaid Services reimbursement for out-patient transitional pass-through payment code (TPT) by June 30, 2022 – 9,410 awards Performance condition was met during the quarter ended March 31, 2022 resulting in the 5,960 shares of common stock being issued in respect of the RSUs and the 3,450 options vesting (although they have not been exercised by the CEO as at the date of this Form 10-Q).
2021 AGM Awards | Performance Based Share Options | Chief Executive Officer | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	9,410
Milestone performance awards to CEO	3,450
Description of the milestone to be achieved for vesting of restricted stock awards	9,410 awards (5,960 RSUs and 3,450 options) - Achieve Japanese approval from Pharmaceuticals and Medical Device Agency (PMDA) and reimbursement code by September 30, 2022
2021 AGM Awards | Performance Based Share Options | Chief Executive Officer | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	9,410
Milestone performance awards to CEO	3,450
Description of the milestone to be achieved for vesting of restricted stock awards	9,410 awards (5,960 RSUs and 3,450 options) - Achieve profitability of the Company’s Burns business for two consecutive quarters by March 31, 2023
2021 AGM Awards | Performance Based Share Options | Chief Executive Officer | Share Based Compensation Award Tranche Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	9,410
Milestone performance awards to CEO	3,450
Description of the milestone to be achieved for vesting of restricted stock awards	9,410 awards (5,960 RSUs and 3,450 options) - Achieve US FDA approval of vitiligo indication by December 31, 2023
2021 AGM Awards | Non Option Performance Based Restricted Stock Units | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	23,840
2021 AGM Awards | Non Option Performance Based Restricted Stock Units | Chief Executive Officer | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	5,960
Milestone performance awards to CEO, vested				5,960
2021 AGM Awards | Non Option Performance Based Restricted Stock Units | Chief Executive Officer | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	5,960
2021 AGM Awards | Non Option Performance Based Restricted Stock Units | Chief Executive Officer | Share-based Payment Arrangement, Tranche Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	5,960
2021 AGM Awards | Non Option Performance Based Restricted Stock Units | Chief Executive Officer | Share Based Compensation Award Tranche Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	5,960
2021 AGM Awards | Market Awards | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	75,240
Milestone performance awards to CEO	27,600
2021 AGM Awards | Market Awards | Chief Executive Officer | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	37,620
Milestone performance awards to CEO	13,800
Description of the milestone to be achieved for vesting of restricted stock awards	37,620 (23,820 RSUs and 13,800 options) - Achieve a doubling based on a 10-day volume-weighted average price (“VWAP”) of the Company’s share price as of the date of the 2021 Annual Meeting (being December 14, 2021) by June 30, 2023.  The target share price is $25.74.
Targeted share Price	$ 25.74
2021 AGM Awards | Market Awards | Chief Executive Officer | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Milestone performance awards to CEO	37,620
Milestone performance awards to CEO	13,800
Description of the milestone to be achieved for vesting of restricted stock awards	37,620 (23,820 RSUs and 13,800 options) - Achieve a market capitalization of the Company of greater than or equal to US$1.25 billion (as compared to market capitalization of ~US$435M as of October 14, 2021) and maintain that market capitalization for at least 30 consecutive calendar days on or before December 31, 2024.
Market capitalization	$ 1,250,000						$ 435,000
2021 AGM Awards | Non Option Market Condition | Chief Executive Officer
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	47,640
2021 AGM Awards | Non Option Market Condition | Chief Executive Officer | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	23,820
2021 AGM Awards | Non Option Market Condition | Chief Executive Officer | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options outstanding number	23,820
Two Thousand And Twenty One A G M Plan | Board of Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting period	12 months
Aggregate number of options and RSU	68,600
Tenure awards to Board of Director	41,400
Tenure option awards to Board of Director	15,300
Tenure awards granted to Board of Director	6,900
Tenure option awards granted to Board of Director	2,550
Two Thousand And Twenty One A G M Plan | Board of Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation by share based payment arrangement vesting percentage	33.33%
Tenure awards to Board of Director	27,200
Tenure option awards to Board of Director	9,850
Tenure awards granted to Board of Director	13,600
Tenure option awards granted to Board of Director	4,925
Two Thousand And Twenty One A G M Plan | Restricted Stock Units (RSUs) | Board of Director | Service Period Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director	26,100
Tenure RSU awards granted to Board of Director	4,350
Two Thousand And Twenty One A G M Plan | Restricted Stock Units (RSUs) | Board of Director | Vesting Percentage Milestone
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tenure RSU awards to Board of Director	17,350
Tenure RSU awards granted to Board of Director	8,675

Share-Based Payment Plans - Sum

Share-Based Payment Plans - Summary Of Stock-based Compensation Is Reflected In The Statements Of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	$ 2,932	$ 1,333
Selling and Marketing Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	329	238
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	2,327	930
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based Payment Arrangement, Expense	$ 276	$ 165

Share-Based Payment Plans - S_2

Share-Based Payment Plans - Summary Of Share Option Activity (Detail)	3 Months Ended
	Mar. 31, 2022shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	1,756,720
Granted	21,900
Exercised	(125)
Expired	(2,275)
Forfeited	(5,050)
Ending balance	1,771,170
Exercisable	911,304
Service Only Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	1,129,126
Granted	21,900
Exercised	(125)
Expired	(2,275)
Forfeited	(5,050)
Ending balance	1,143,576
Exercisable	592,085
Performance Based Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	599,994
Ending balance	599,994
Exercisable	319,219
Market Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance	27,600
Ending balance	27,600

Share-Based Payment Plans - S_3

Share-Based Payment Plans - Summary Of Company Unvested RSUs (Detail)	3 Months Ended
	Mar. 31, 2022shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	297,490
Unvested RSUs vested	(29,713)
Unvested RSUs ending balance	267,777
Non Options Service Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	114,757
Unvested RSUs ending balance	114,757
Non Option Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	135,093
Unvested RSUs vested	(29,713)
Unvested RSUs ending balance	105,380
Non Option Market Condition
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs beginning balance	47,640
Unvested RSUs ending balance	47,640

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Tax expense	$ 4,000	$ 10,000
Deferred tax assets valuation allowance			$ 51,300,000				$ 46,900,000
Unrecognized income tax benefits	$ 0		0
Tax Cut And Jobs Act
Income Tax Disclosure [Line Items]
Percentage of tax amount likely to be realised				50.00%	50.00%	50.00%
Tax Year 2026 through 2038
Income Tax Disclosure [Line Items]
Net operating loss carryforwards			$ 21,700,000
Earliest Tax Year
Income Tax Disclosure [Line Items]
Open tax year			2026
Latest Tax Year
Income Tax Disclosure [Line Items]
Open tax year			2038
Internal Revenue Service (IRS)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards			$ 122,000,000
State and Local Jurisdiction
Income Tax Disclosure [Line Items]
Net operating loss carryforwards			$ 79,700,000
State and Local Jurisdiction | Earliest Tax Year
Income Tax Disclosure [Line Items]
Open tax year			2026
State and Local Jurisdiction | Latest Tax Year
Income Tax Disclosure [Line Items]
Open tax year			2041
Her Majesty's Revenue and Customs (HMRC)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards			$ 31,900,000
Australian Taxation Office
Income Tax Disclosure [Line Items]
Net operating loss carryforwards			$ 38,200,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Reconciliation of The Basic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss	$ (9,463)	$ (5,997)
Weighted-average common shares – outstanding, basic	24,937,999	22,734,335
Weighted-average common shares – outstanding, diluted	24,937,999	22,734,335
Net loss per common share, basic	$ (0.38)	$ (0.26)
Net loss per common share, diluted	$ (0.38)	$ (0.26)

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay	6.00%
Employers contribution to retirement plan	$ 233,000	$ 221,000
Deferred Compensation Plans
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting period	2 years
Employer contributions to deferred compensation plan	$ 84,000	$ 0
Deferred compensation plan liability	$ 571,000		$ 262,000
Deferred Compensation Plans | Vesting on Year One
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting percentage	25.00%
Deferred Compensation Plans | Vesting on Year Two
Defined Benefit Plan Disclosure [Line Items]
Employer matching contributions, Vesting percentage	75.00%
Deferred Compensation Plans | Minimum
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay	4.00%
Deferred Compensation Plans | Maximum
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employers matching contribution percentage of employees pay	6.00%

Retirement Plans - Summary of F

Retirement Plans - Summary of Fair Values of Company's Deferred Compensation Plan Assets and Liability (Detail) - Deferred Compensation Plans - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Corporate-owned life insurance policies	$ 586	$ 304
Level 2
Defined Benefit Plan Disclosure [Line Items]
Corporate-owned life insurance policies	$ 586	$ 304